Despite being one of the most expensive drugs in the world, GlaxoSmithKline’s gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or “bubble boy” syndrome. The drug, which costs
read moreScore one for Novartis in its quest to expand its cancer-fighting combo, Tafinlar and Mekinist. On Monday, the FDA bestowed its “breakthrough” tag on the pair in adjuvant, BRAF V600 mutation-positive melanoma, setting it up for a quick trip down
read moreIn less than a week, Johnson & Johnson has successfully challenged two talc verdicts and wiped away nearly $500 million in liabilities. A judge in Los Angeles on Friday reversed the company’s largest loss to date, a $417 million verdict
read moreEven as pricing pressure on its diabetes portfolio has led Eli Lilly to cut 3,500 jobs by year-end, the drugmaker today said it is moving forward with a $72 million upgrade to its insulin manufacturing, part of an $850 million
read morePublic Health England has launched a major new campaign designed to further reign in inappropriate use of antibiotics, as estimates show that around 5,000 people in England alone die every year because of antimicrobial resistance. More: PHE launches campaign to
read moreWith the awards ceremony edging closer, the Marketer of the Year and Communications Team of the Year finals concluded last week. More: Marketer & Communications Team of the Year: Finalists announced as countdown begins! Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals